Novel Horizon Health Rises 3% After Signing Strategic Collaboration with Takeda China for H. pylori Full-Course Management

　　New Horizon Health(06606) rose 3% in the afternoon, currently trading at HK$20.7, with a turnover of HK$19.8107 million.

New Horizon Health recently signed a strategic cooperation agreement with Takeda China at the Shanghai CIIE to jointly develop a full-process management solution for Helicobacter pylori patients in China. Through innovative collaboration across diagnosis and treatment fields, they aim to provide comprehensive management services from screening, diagnosis, and treatment to follow-up for Helicobacter pylori infections in China.

Editor: Lu Yu Jun